Similar articles

• [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].

  Pfeilschifter J. Pfeilschifter J. Orthopade. 2001 Jul;30(7):462-72. doi: 10.1007/s001320170079. Orthopade. 2001. PMID: 11515185 Review. German.
• Selective estrogen receptor modulators.

  Kearney CE, Purdie DW. Kearney CE, et al. Climacteric. 1998 Jun;1(2):143-7. doi: 10.3109/13697139809085530. Climacteric. 1998. PMID: 11907917 Review. No abstract available.
• [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 May 29;145(22):57. MMW Fortschr Med. 2003. PMID: 12866287 German. No abstract available.
• [Treatment of postmenopausal osteoporosis with raloxifene].

  Fedelesova V, Chylova K, Dzurik. Fedelesova V, et al. Bratisl Lek Listy. 2000;101(9):527-8. Bratisl Lek Listy. 2000. PMID: 11187059 Clinical Trial. Slovak.
• Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

  Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Cauley JA, et al. Breast Cancer Res Treat. 2001 Jan;65(2):125-34. doi: 10.1023/a:1006478317173. Breast Cancer Res Treat. 2001. PMID: 11261828 Clinical Trial.